Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
STSTLNthis companyStarling Oncology, Inc.	$4.21	-10.74×	-34.09×	1.07×	-14.25×	-250.7%	15.2%	-7.2%	-12.1%	385.5%	-35.7%	-5.2%	-6.6×	-1.65×	-3.2×	1.59×	0.0%	—	—	2	C
LLYEli Lilly and Company	$1,396.54	46.58×	36.37×	14.81×	31.57×	-47.2%	83.0%	45.6%	31.7%	77.8%	30.2%	0.9%	1.6×	1.12×	37.34×	1.58×	0.6%	7	9.47	3	B
JNJJohnson & Johnson	$279.38	18.82×	6.18×	5.35×	12.97×	7.8%	67.9%	27.2%	28.5%	32.9%	13.7%	3.9%	0.59×	0.69×	26.36×	1.03×	2.5%	7	5.49	3	B+
ABBVAbbVie Inc.	$292.30	96.41×	-123.96×	6.63×	26.61×	-55.6%	70.2%	32.8%	6.9%	-129.2%	13.0%	4.4%	-21.12×	3.62×	6.94×	0.67×	2.9%	7	2.9	1	C-
MRKMerck & Co., Inc.	$147.64	14.42×	5.01×	4.06×	10.59×	19.4%	72.0%	36.2%	28.1%	34.7%	18.3%	4.7%	0.96×	1.27×	17.31×	1.54×	3.1%	6	3.99	1	C-
UNHUnitedHealth Group Incorporated	$396.17	24.95×	3.19×	0.67×	15.37×	-34.0%	18.5%	4.2%	2.7%	12.8%	8.2%	5.4%	0.83×	2.34×	4.74×	0.79×	2.6%	8	2.63	3	B
Peer median	—	24.95×	5.01×	5.35×	15.37×	-34.0%	70.2%	32.8%	28.1%	32.9%	13.7%	4.4%	0.83×	1.27×	17.31×	1.03×	2.6%	7	3.99	3	—